Cabozantinib

(Cometriq®)

Cabozantinib

Drug updated on 9/4/2024

Dosage FormCapsule (oral; 20 mg, 80 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Cometriq (cabozantinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
  • This summary is based on the review of 10 systematic review(s)/meta-analysis(es). [1-10]
  • Metastatic Merkel Cell Carcinoma (MCC) and Medullary Thyroid Carcinoma (MTC): Cabozantinib effectively controlled MCC and MTC in an 83-year-old immunosuppressed male, with no MCC relapse after 24 months of treatment.
  • Glucose and Lipid Metabolism in Thyroid Malignancies: Cabozantinib was associated with elevated glucose levels (prevalence: 1-17%), hypercholesterolemia (prevalence: 4-40%), and hypertriglyceridemia (prevalence: 1-86%).
  • Renal Cell Carcinoma (RCC), Castration-Resistant Prostate Cancer (CRPC), Non-Small Cell Lung Cancer (NSCLC): Cabozantinib in combination therapy showed improved progression-free survival (PFS) compared to standard treatments.
  • Radioiodine-Refractory Differentiated Thyroid Cancer (RAIR-DTC): Cabozantinib significantly improved PFS compared to placebo, though the effect size was not specified.
  • Cabozantinib was associated with metabolic alterations, including elevated glucose levels and hyperlipidemia, potentially leading to severe, life-threatening events.
  • Grade 3 or higher adverse events occurred in 48.5% of patients with medullary thyroid carcinoma (MTC) treated with TKIs, and 44.7% discontinued treatment due to these adverse events.
  • Most patients with thyroid cancer experienced adverse effects, with substantial impact on the management of long-term outcomes.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information.2020Exelixis, Inc. Alameda, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines